A091990 Stock Overview
Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Celltrion Healthcare Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩75,900.00 |
| 52 Week High | ₩81,400.00 |
| 52 Week Low | ₩53,600.00 |
| Beta | 0.22 |
| 11 Month Change | -3.68% |
| 3 Month Change | 18.04% |
| 1 Year Change | 26.92% |
| 33 Year Change | -43.85% |
| 5 Year Change | 29.67% |
| Change since IPO | 78.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| A091990 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | 0% | 3.6% | 2.3% |
| 1Y | 26.9% | -4.4% | -3.8% |
Return vs Industry: A091990 exceeded the KR Healthcare industry which returned 21.2% over the past year.
Return vs Market: A091990 exceeded the KR Market which returned 9.7% over the past year.
Price Volatility
| A091990 volatility | |
|---|---|
| A091990 Average Weekly Movement | 5.6% |
| Healthcare Industry Average Movement | 10.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A091990 has not had significant price volatility in the past 3 months.
Volatility Over Time: A091990's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 149 | Hyoung Ki Kim | www.celltrionhealthcare.com |
Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. Its products include Remsima, a monoclonal antibody biosimilar that is used for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, Crohn's disease in children, psoriasis, and psoriatic arthritis; Truxima, which is used for lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis and microscopic polyangiitis, and rheumatoid arthritis; Herzuma that is used for metastatic breast cancer, early breast cancer, and metastatic gastric cancer; and Remsima SC, which is used for rheumatoid arthritis. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd.
Celltrion Healthcare Co., Ltd. Fundamentals Summary
| A091990 fundamental statistics | |
|---|---|
| Market cap | ₩11.91t |
| Earnings (TTM) | ₩43.13b |
| Revenue (TTM) | ₩2.22t |
276.1x
P/E Ratio5.4x
P/S RatioIs A091990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A091990 income statement (TTM) | |
|---|---|
| Revenue | ₩2.22t |
| Cost of Revenue | ₩1.59t |
| Gross Profit | ₩624.94b |
| Other Expenses | ₩581.81b |
| Earnings | ₩43.13b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 274.94 |
| Gross Margin | 28.18% |
| Net Profit Margin | 1.94% |
| Debt/Equity Ratio | 17.1% |
How did A091990 perform over the long term?
See historical performance and comparison